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Tobacco use in mental health in general and bipolar disorder in particular remains disproportionally common, despite declining 
smoking rates in the community. Furthermore, interactions between tobacco use and mental health have been shown, indicating 
the outcomes for those with mental health disorders are impacted by tobacco use. Factors need to be explored and addressed 
to improve outcomes for those with these disorders and target specific interventions for people with psychiatric illness to cease 
tobacco smoking. In the context of bipolar disorder, this review explores; the effects of tobacco smoking on symptoms, quality 
of life, suicidal behaviour, the biological interactions between tobacco use and bipolar disorder, the interactions between tobacco 
smoking and psychiatric medications, rates and factors surrounding tobacco smoking cessation in bipolar disorder and suggests 
potential directions for research and clinical translation. The importance of this review is to bring together the current under-
standing of tobacco use in bipolar disorder to highlight the need for specific intervention.
KEY WORDS: Bipolar disorder; Smoking; Smoking cessation; Quality of life; Psychotropic drugs.
INTRODUCTION
Tobacco smoking is a leading preventable cause of poor 
health and premature mortality.1) While tobacco smoking 
rates in the general population are declining, they remain 
raised in cohorts with psychiatric problems.2) Nicotine, 
the primary active compound found in tobacco, is highly 
addictive.3) High rates of tobacco smoking have been de-
scribed in bipolar disorder and are associated with poorer 
outcomes.4) Tobacco smoking is approximately 2-3 times 
more prevalent in bipolar disorder than in the general pop-
ulation, with estimates ranging from 60-70% in bipolar 
patients compared to 25-30% in the general popula-
tion.2,4,5) This elevated smoking rate may not only impact 
on the course of the disorder but may also contribute to 
higher levels of tobacco-related morbidity and mortality.6)
Despite high rates of comorbidity and related morbid-
ity, there is a only modest field of research focusing on 
smoking among individuals with bipolar disorder and the 
relationship with important clinical and public health out-
comes including: the effects on mood symptoms, quality 
of life, suicidal behaviour, implications for pharmaco-
logical treatment, barriers to cessation, and the biological 
pathways modulating the expression of pathophysiology. 
Moreover, results from existing studies spanning these 
topics appear conflicting, suggesting uncertainly exists in 
the literature. 
Some authors have argued that tobacco smoking results 
in poorer treatment outcomes in bipolar disorder,7-12) 
whereas other researchers have not found such a rela-
tionship.13,14) Variance between studies may be due to de-
sign factors including the sample size, the sample se-
lection inconsistent measurements of smoking behaviour, 
and the methodological design of the studies. Given this, 
the following review aims to explore the issues specific to 
smoking cessation in bipolar disorder and provide the 
most clarity regarding treatment options and outcomes.
A comprehensive search using PubMed and Google 
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Scholar was conducted using the terms “smoking and ma-
nia”, “smoking and bipolar disorder” and “nicotine de-
pendence and bipolar disorder”. The purpose of the cur-
rent review was to explore the effects of tobacco smoking 
in bipolar disorder, examining the relationship between 
smoking and mood symptoms (e.g., depression and ma-
nia), quality of life, suicidal behaviour, biological inter-
actions between the pathophysiology of the disorder and 
the addiction to tobacco, as well as the effects of tobacco 
smoke on medication and of smoking cessation. Specifi-
cally, this paper discusses pertinent studies spanning clin-
ical and public health topics, addressing current gaps in 
the field and extending previous reviews conducted, with 
an aim of prompting further research in the nascent field. 
Such an evidence base may also provide a context for 
guiding policy makers and informing clinical practice. 
MAIN SUBJECTS
Tobacco Smoking Cessation and Effects on Mood 
Symptoms 
At a population level, mood symptoms such as mania or 
depression appear to be associated with tobacco use. The 
presence of mania and hypomania is associated with 3.9 
and 3.5 times greater likelihood of tobacco dependence in 
the psychiatric population, respectively.15) Additionally, 
during acute tobacco smoking cessation, those with bipo-
lar disorder may have higher risks of experiencing ma-
nia,16,17) and transient depressive recurrence.18) Further-
more, Adan et al.19) have reported low mood scores in 
highly dependent smokers, intermediate mood scores in 
low dependent smokers and high mood scores in 
non-smokers, suggesting the role nicotine dependence 
plays in mood regulation. Another issue regarding bipolar 
disorder and tobacco smoking cessation is the potential ef-
fect of cessation on mood symptoms. Although there have 
been case reports of mania,16,17) and depression,18) follow-
ing abrupt nicotine withdrawal, there are few double blind 
placebo controlled studies that have looked at the effect of 
tobacco cessation on mood. A key recent meta-analysis 
has shown that on aggregate, mental health symptoms, 
particularly depression, improve in those who quit smo-
king.20)
Those with bipolar disorder might thus be proposed to 
have an increased susceptibility to tobacco smoking de-
spite the observation that many patients start to smoke be-
fore the onset of their illness.21-23) Research shows that 
most smokers take up the habit as teenagers,24) with recent 
statistics in Australia revealing that in 2010, the age of ini-
tiation was 16.25) Regarding the age of onset in bipolar dis-
order, for bipolar type I the average age of onset is 23 years 
for males and 26 years for females, and for bipolar type II, 
the age of onset is 29.7 years for males and 30.1 years for 
females.26) A line of research has postulated that enduring 
alterations in neurophysiology as a result of tobacco abuse 
may unmask an underlying vulnerability to affective dis-
orders, including bipolar disorder.19,27,28) However, the 
mechanisms underlying the relationship between tobacco 
smoking and bipolar disorder are clearly bidirectional, 
complex and multifactorial.13,29) Therefore, while it is 
probably correct that in most instances tobacco smoking 
behaviour pre-dates and is a risk factor for bipolar dis-
order, caution is recommended when interpreting these 
findings and implying causality.
Specific associations between tobacco smoking status 
and symptom characteristics of the disorder have been 
described.7,8,11,12,30,31) In an early study looking at the role 
of tobacco smoking and psychotic symptom status in bi-
polar disorder, Corvin et al.12) examined the effect of 
smoking severity on a sample of 92 patients with bipolar 
disorder. Tobacco smoking was less prevalent in less 
symptomatic patients whereas pervasiveness of smoking 
was correlated with severity of symptoms (particularly 
psychotic symptoms). This was a cross-sectional study 
with a small sample size using self-report measures which 
should be noted when interpreting the results, as no ob-
jective measure such as blood test were used to detect nic-
otine use. A recent prospective and naturalistic study over 
24 months examined the effect of tobacco smoking on 
mental health outcomes in 239 patients with schizo-
affective and bipolar disorder,11) and found that in both 
schizoaffective and bipolar disorder, daily smokers had 
poorer prognosis in terms of depression and overall bipo-
lar symptomatology (assessed using the Clinical Global 
Impressions−Depression and Clinical Global Impre-
ssions−Overall Bipolar scales) and longer stays in hospi-
tal compared with non-smokers. An important limitation, 
similar to Corvin and colleagues,12) is that the study did 
not objectively measured nicotine dependence and used 
self-report measures. This is again an important issue as 
varying levels of nicotine dependence may affect overall 
scores and mood symptomatology more than simply as-
sessing daily smoking rates reported by the patients. Daily 
smoking rates do not necessarily address smokers’ levels of 
nicotine addiction amongst patients with bipolar disorder. 
Other studies have reported a link between tobacco 
smoking and worse outcomes in both mania and depres-
sion in bipolar disorder.7,8,10,30,31) In particular, a large 
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study of 399 patients with bipolar disorder reported that a 
lifetime history of tobacco smoking was significantly re-
lated to earlier onset of the first depressive or manic epi-
sode, greater symptom severity, poorer functioning, a life-
time history of suicide attempt comorbid anxiety and sub-
stance abuse.10) In addition, results from the Systematic 
Treatment Enhancement Program for Bipolar Disorder 
(STEP-BD) have linked tobacco smoking to clinical vari-
ables including more lifetime manic and depressive symp-
toms, rapid cycling illness, comorbid mental disorders, 
substance abuse and active illness.8) However cross-sec-
tional studies have showed inconsistent findings.13,14) In 
the most recent study, illness severity, number of episodes, 
history of psychotic symptoms, history of suicide at-
tempts, age at onset of the illness, abuse of psychoactive 
drugs, current clinical status and other demographic varia-
bles and their relationship with tobacco smoking were ex-
amined in a sample of 102 participants with bipolar 
disorder. There was a higher tobacco smoking prevalence 
in this population and a higher presence of alcohol and 
other drugs use and earlier age of illness onset in those pa-
tients with bipolar disorder who smoked more. No other 
association with regard to illness severity was found in 
this study. However, the authors caution against general-
isation due to the small sample size and the cross sectional 
study design. Furthermore, nicotine levels were not meas-
ured in this study. Similarly, Cassidy et al.13) reported no 
association between smoking and psychosis in patients 
with bipolar disorder, but no measures of mood were in-
cluded in the analysis.
Inconsistent findings on the impact of tobacco smoking 
on prognosis in bipolar disorder have also been recently 
reported in a comprehensive review on the effects of 
smoking on the health outcomes in bipolar disorder.32) In 
the reviewed studies, tobacco smoking was correlated 
with rapid cycling,4,8,33) more affective episodes,32,33) ele-
vated risk of psychotic episodes,12) and more time spent in 
hospital,20,30) in some studies but not in others. Individual 
differences in nicotine dependence may account for the 
variability of the findings between studies. Methodologi-
cal complexities including limited number of participants, 
bipolar patients who are nicotine dependent versus smok-
ers who are non-nicotine dependent, admixtures of pro-
spective and cross-sectional studies, diverse measures and 
lack of objective biological markers might account for the 
difference observed.
Quality of Life and Tobacco Smoking in Bipolar Disorder
Tobacco use enhances mortality and decreases quality 
of life through a number of smoking-related health dis-
eases such as cardiovascular, cancer or respiratory condi-
tions.34) Tobacco smoking has also been related to more 
severe course, relapse and higher number of hospital-
izations,20) and is also associated with an elevated risk of 
concomitant substance use disorders.24) Few studies have 
examined the quality of life in smokers versus non-smoker 
with bipolar disorder. Consistent findings across studies 
have shown that quality of life is higher in non-smokers 
and occasional smokers compared with nicotine depend-
ent bipolar patients.11,21,22) Smoking has also been asso-
ciated with low socioeconomic status in patients with bi-
polar disorder,8) and with the risk of anxiety disorders in 
the general population,23) which may be moderating or 
mediating pathways.
In a study examining the quality of life in bipolar dis-
order in comparison with that of the general population, 
48 euthymic and 60 non-euthymic bipolar patients were 
compared with 1210 controls using the physical and men-
tal component scores of the Medical Outcomes Survey 
36-item Short Form Health-Survey (SF-36).21) Clinical 
and course of illness variables and their association with 
low physical and mental quality of life were explored in-
cluding manic and depressive symptoms and consump-
tion of other addictive substances. Lower mental quality 
of life was associated with longer duration of illness and 
early onset in bipolar patients. A higher presence of de-
pressive symptoms, nicotine dependence and lack of so-
cial support was also reported in the bipolar group. Further 
studies have replicated this association. Quality of life in 
terms of physical health, psychological wellbeing and en-
vironmental and social relationships was lower in bipolar 
patients with nicotine dependence than in those without 
nicotine dependence.22) Worse health related quality of 
life scores were also found for daily smokers.11)
It is plausible that tobacco smoking in bipolar disorder 
might be indirectly influencing this construct through 
modifiable lifestyle factors that have also shown to be re-
lated to bipolar disorder. Poorer diet and lower levels of 
physical activity have been associated with smokers, in 
addition to these factors already being present in bipolar 
disorder.24-27) Furthermore, tobacco smoking may play a 
detrimental role in sleep quality for those with bipolar 
disorder. Sleep disturbance has comprehensively and in-
dependently been associated with poor health-related 
quality of life.35) In a study including 252 participants with 
mood disorder, the severity of the disorder was positively 
associated with the mean number of cigarettes smoked per 
day and with greater levels of fatigue. Additionally, mild 
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to severe symptoms of insomnia were related to the level 
of nicotine dependence.28) Differences between smokers 
and non-smokers in circadian rhythmicity and mood var-
iation have been reported in the general population.19) 
Altered sleep patterns play a detrimental role in bipolar 
disorder,29) as disrupted night time sleep and day time 
mood have been proposed to be mutually reinforcing.36) 
This bidirectional model, known as the sleep-mood cycle, 
is of particular importance to bipolar disorder and insom-
nia.36) Disruptions in circadian rhythms have been identi-
fied as a major trigger for the onset and relapse of bipolar 
disorder.37-40) These modifiable lifestyle factors not only 
play a role in quality of life for bipolar disorder, but these 
relationships imply that they could play a critical part in 
the management of the illness.
The Relationship between Tobacco Smoking and 
Suicidal Behaviour in Bipolar Disorder 
To date, many studies have identified associations be-
tween psychiatric disorders, comorbidities and suicide 
attempts. This has been demonstrated across several stud-
ies utilizing adequate study designs with large sample 
sizes.41) In particular, tobacco smoking has also been in-
dependently linked to increased risk of suicidality, an as-
sociation that was sustained after adjustment for psychi-
atric disorders.42)
Individuals with bipolar disorder, have higher rates of 
suicide than the general population.43) Moreover, the con-
tribution of disability and mortality related to physical 
causes of death, suicide and injuries incurred via self-harm 
in this group are significant.10) Due to the deleterious out-
comes for individuals and significant burden that both to-
bacco smoking and suicidal behaviour incurs, it is neces-
sary to understand the role of this potentially modifiable 
lifestyle factor and its link to suicidal behaviour in this 
group to reduce mortality and disability. 
Several studies have demonstrated associations be-
tween tobacco smoking in bipolar disorder and suicidal 
behaviour.8,10,33,44,45) In one study, predictors of suicidal 
acts were investigated in a 2-year follow-up study of pa-
tients (n=308) presenting with major depressive disorder 
or bipolar disorder at baseline.44) Cox proportional haz-
ards regression analyses revealed that tobacco smoking 
was among the strongest predictors for future suicidal 
acts, alongside history of suicidal acts and self-reported 
severity of depression. Furthermore, among other sig-
nificant clinical predictors for suicidal acts were presence 
of a comorbid Cluster B personality disorder, and ag-
gressive and impulsive personality traits. These person-
ality features and traits have been shown to be risk factors 
for self-mutilation, help-seeking suicide threats and/or at-
tempts and completed suicide,46-48) and frequently co-oc-
cur with bipolar disorder.49) It is possible that comorbidity 
among impulsive/aggressive features and smoking in-
creases the risk for suicidal behaviours in bipolar disorder.
A retrospective clinical study (1999-2004) also demon-
strated significant associations between lifetime tobacco 
smoking and suicide attempts in patients with bipolar dis-
order, after adjusting for other psychiatric comorbidities 
and measures of disability and functional impairment.10) 
Finally, subsequent prospective analyses have also re-
ported that tobacco smoking was associated with in-
creased risk of suicidality in individuals with bipolar dis-
order (n=106), throughout the course of a nine-month fol-
low-up.35) These baseline associations were not sustained 
after adjustment for impulsivity in the models. Moreover, 
small sample sizes precluded further analyses examining 
associations between impulsivity, smoking and suicide 
attempts. 
The increased risk for suicide attempts among those 
with bipolar disorder, and who smoke, appears to true 
even for youths. The Course and Outcome of Bipolar 
Youth Study examined 212 youths (7-17 years) with bipo-
lar disorder and correlates. Differences between three 
groups of tobacco smoking status (daily, never smoked, 
ever smoked) were observed, with daily smokers having a 
higher lifetime prevalence of suicide attempts. Logistic 
regression found those with a history of tobacco smoking 
had approximately a three-fold increased risk of lifetime 
suicide attempt compared to those without. However, it 
was beyond the scope of the study to examine the preva-
lence and correlates of nicotine dependence among the 
youths with bipolar disorder. Further, longitudinal analy-
ses of subsequent follow-up visits may elucidate temporal 
relationships smoking and suicidality in the younger with 
bipolar disorder. 
Contrary these findings, others have reported no sig-
nificant associations for tobacco smoking and suicidality 
in bipolar disorder in longitudinal analyses.50-52) In one 
study, 40.5% of those who had attempted and/or com-
pleted suicide over the observational period (2 years) were 
smokers.48) Whilst there was an initial trend for associa-
tions between baseline tobacco smoking status and in-
creased risk for suicide attempts, the association was not 
sustained in logistic regression models,52) as was the case 
in another study with a similar follow-up period.51) An ad-
ditional prospective study also reported that tobacco 
smoking did not predict suicide attempts over the ob-
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servational period (18 months).50) A review examining the 
clinical and health outcomes of a number of psychiatric 
disorders, also suggested that associations between tobac-
co smoking and suicidal behaviour in patients with bipolar 
disorder was inconclusive.32)
These studies highlight that tobacco smoking may be 
independently associated with suicide attempts in in-
dividuals with bipolar disorder. However, there remains 
areas of uncertainty about the relationship between tobac-
co smoking and bipolar disorder in regards to suicidal 
behaviour. It may be that personality variables (linked to 
impulsivity) may be important effect modifiers in the rela-
tionship between tobacco smoking and suicidality, partic-
ularly during acute phases of the disorder. Examining the 
potential role of personality as a mediating and/or moder-
ating variables in future studies examining tobacco smok-
ing and comorbidities is warranted. 
Biological Interactions between the Pathophysiology of 
Bipolar Disorder and Tobacco Addiction 
To date, operative mechanisms linking tobacco smok-
ing and bipolar disorder remain unclear. In unipolar de-
pression, the role of neurotransmitters has been hypoth-
esized. Associations may be related to lower levels of 
brain serotonergic function in smokers.53) Lower levels of 
serotonin in both humans and primates have been linked 
with higher levels of impulsive, novelty seeking 
behaviour.54) However, given discrepancies between the 
underlying biology in unipolar and bipolar depression 
(see next section), caution needs to be taken when consid-
ering these links. Additionally, dysregulation of the dop-
amine and glutamatergic systems and their inputs to dif-
ferent regions of the brain (particularly prefrontal cortex 
and basal ganglia) have been linked to the maintenance 
and relapse of addictive behaviour.55-57) Nicotine is a nic-
otinic cholinergic receptor agonist that causes the release 
of both dopamine and norepinephrine. These two neuro-
transmitters are implicated in the pathophysiology of bi-
polar disorder, and are also thought to play a key role in 
addiction. This may influence susceptibility of people 
with bipolar disorder to the rewarding effects of nicotine. 
Furthermore, smokers have reduced monoamine oxidase 
which is a potential pharmacological effect of tobacco 
smoke as it prolongs the synaptic presence of neuro-
transmitters involved in mood regulation (i.e., serotonin 
and dopamine).58) Cholinergic- monoamine pathway in-
teractions may link nicotine dependence and bipolar dis-
order given the putative role of dopamine, serotonin nor-
epinephrine and glutamine,4,59) in the pathogenesis of both 
bipolar disorder and nicotine addiction and the role of 
monoamine neurotransmitters in mood disorders.
In this regard, cyclical dopamine dysregulation has 
been proposed as a central mechanism underlying bipo-
larity.60) The activation of the mesolimbic dopaminergic 
pathways through the diffuse cholinergic innervations in 
the brain is thought to play a salient role in the generation 
of reward and reinforcement of tobacco smoking.61) 
Further to this, dynamic desensitization of nicotinic chol-
inergic, dopaminergic and other downstream receptors 
may account not only for nicotine tolerance and with-
drawal symptoms but also for smoking conditioning 
through the rewarding effects of nicotine in the brain. An 
increase in dopaminergic transmission would predom-
inate during the manic phase there is whereas a secondary 
down regulation of receptors would eventually dampen 
the cycle learning to a phase of decreased dopaminergic 
transmission, characteristic of the depressive phase.60) 
This theory of the role of the dopaminergic system pro-
vides support for the relationship between tobacco smok-
ing and mood disorders. There might be a number of other 
underlying neurobiological mechanisms to account for 
this relationship given the vast array of other neuro-
chemicals triggered by nicotine. Enduring changes in ex-
citatory glutamatergic synapses on the nucleus ac-
cumbens are induced by nicotine use,55,62) and have been 
shown to be involved in drug relapse.63) Recently, dis-
turbances in glutamatergic function have also been im-
plicated in the pathophysiology of mood disorders (major 
depressive disorder and bipolar disorder).46-49) The role of 
inflammation and oxidative and nitrosative stress as a 
plausible mediator for the development of depressive and 
bipolar disorders and its relationship to tobacco use have 
also been examined in recent years. The literature also 
provides some support for a potential interaction between 
tobacco smoking and the neuroprogressive course of the 
disorders as these pathways are affected by exposure to to-
bacco smoke components such as nicotine and free 
radicals.64-66) 
Effects of Tobacco Smoking on Pharmacological 
Treatment in Bipolar Disorder
The effect of tobacco smoking on the impact of the me-
tabolism of many psychotropic medications used in the 
treatment of bipolar disorder is well documented.4,11,67) 
Polycyclic aromatic hydrocarbons in tobacco smoke, in-
crease the metabolism of some psychotropic medications, 
including olanzapine, clozapine, haloperidol and fluvoxa-
mine.4) This is largely mediated via the induction of the 
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hepatic cytochrome P450 enzyme 1A2 by the polycyclic 
aromatic hydrocarbons found in tobacco smoke, leading 
to lower serum levels of drugs including olanzapine as 
well as other antipsychotics, antidepressants and benzo-
diazepines. This may be a pathway whereby tobacco 
smoking reduces the therapeutic benefits of taking these 
medications. This results in smokers with bipolar requir-
ing an increased dose, approximately 50% higher, to ach-
ieve an adequate therapeutic response.67)
Additionally, some case reports suggests that a sub-
stantial increase in tobacco smoking can lead to an in-
crease in psychiatric symptoms among individuals with 
bipolar disorder who are taking olanzapine, at least in part 
due to the reduction in medication levels explored the dose 
dependent effect of tobacco smoking on serum concen-
trations of clozapine and olanzapine.67) The mean serum 
concentration to dose ratio was twice as high in non-smok-
ers compared to smokers for both olanzapine and cloza-
pine, leading to authors to consider differential starting 
doses in smokers compared to non-smokers. 
It has been further reported that nicotine’s activation of 
the sympathetic nervous system may reduce the sedating 
effects of benzodiazepines and the capacity of beta block-
ers to lower heart rate and blood pressure.4) The evidence 
that tobacco smoking not only interferes with a range of 
different medications, points to the widespread effect that 
nicotine and tobacco smoke plays on multiple neuro-
transmitter and brain systems.11,67-69) Dani and De Biasi68) 
suggest fast nicotinic transmission is used throughout the 
peripheral nervous system and at the neuromuscular junc-
tions, leading to body-wide impacts. This view is sup-
ported by Laviolette and van der Kooy,69) who state that 
nicotine produces diverse neurophysiological, motiva-
tional and behavioural effects throughout several brain re-
gions via multiple neurochemical pathways. 
The far-reaching ability of nicotine to produce changes 
in multiple neurotransmitter systems is possibly through 
the widespread cholinergic innervations that nicotine 
plays on the brain. As nicotine is a nicotinic cholinergic re-
ceptor agonist it enhances the release of a cascade of neu-
rotransmitters including dopamine, serotonin, norepine-
phrine and glutamine. Agents that drive dopamine such as 
cocaine and amphetamine are among the best models of 
mania, while dopamine D2 antagonists are robustly an-
ti-manic and include several antipsychotic agents.61) 
Nicotine may thus indirectly drive dopamine itself as well 
as counteract the effects of pharmacological interven-
tions, firstly via its psychostimulant properties, and sec-
ondly via pharmacokinetic interactions as highlighted 
above.
Hutchison et al.70) looked at the atypical antipsychotic, 
olanzapine, in attenuating cue elicited craving for toba-
cco. The hypothesis was that if mesolimbic dopaminergic 
activity is associated with cue-elicited cravings for tobac-
co, a dopaminergic antagonist should attenuate cue-eli-
cited cravings for tobacco. Olanzapine attenuated cue eli-
cited craving for tobacco, but did not moderate the sub-
jective effects of tobacco smoking in a randomly assigned 
five day placebo controlled trial. However, dopamine an-
tagonists decrease the pleasure, reinforcement and reward 
of tobacco smoking, which might lead to increase smok-
ing behaviour.71) 
Tobacco Smoking Cessation and Bipolar Disorder
The rate of successful cessation attempts for people 
with mental illness is low. Data from the United States 
2002 National Survey on Drug Use and Health demon-
strated that the quit rate was 49% for former smokers with 
no serious psychological distress, determined using the 
K6 scale, whereas the quit rate was 29% for former smok-
ers with serious psychological distress.72) The reason for 
these reduced quit rates has been examined by tobacco 
control researchers, with one view describing the concept 
of ‘hardening’ and ‘hard-core smokers’, where reduced 
quit rates are attributed to greater difficulty in quitting or 
less willingness to do so.73) In the general population, evi-
dence of hardening remains elusive as tobacco smoking 
rates continue to decline; however, amongst people with 
bipolar and other major psychiatric disorders smoking 
rates have not declined at the same rate and hardening may 
be a factor. However, it is very unlikely to fully explain the 
disparity in quit rates between the mentally ill and general 
populations. Smokers with mental illness may be as moti-
vated to quit smoking tobacco as smokers without a cur-
rent mental illness. This has been demonstrated in studies 
of an inpatient population58) in Australia. There is some 
data indicating less readiness to quit amongst bipolar pa-
tients in India74); however, this may be attributed to a less-
er awareness of the health risks of tobacco smoking in that 
specific population. This suggests that willingness to quit 
may not be a factor in the discrepancies between quit rates 
between mentally ill and not mentally ill smokers. Greater 
difficulty in quitting smoking may still be a ‘hardening’ 
factor in this population as most readily available tobacco 
smoking cessation strategies have been developed for the 
general population and may not be as effective for men-
tally ill smokers. 
Other non-hardening factors may also be applicable to 
Tobacco Use in Bipolar Disorder 7
this population, including less awareness of the health 
risks associated with tobacco smoking, a factor likely to 
vary considerably between and even within different 
countries. There are reports that some people with mental 
illness may feel alienated from approaching mainstream 
tobacco smoking cessation services.8) However, the rea-
sons for the disparity in smoking cessation rates between 
mentally ill and not mentally ill people have not been suf-
ficiently researched. 
In a review of tobacco smoking cessation in bipolar dis-
order, George et al.33) found just 11 clinical studies on bi-
polar disorder and tobacco addiction showing that people 
with bipolar disorder have much lower quit rates than 
smokers without a comorbid condition. Several case re-
ports as reviewed by Dome et al.32) suggested that vareni-
cline treatment, for tobacco cessation, may provoke mania 
in patients with or without a history mood disorders. 
However this has not been borne out by large scale well 
designed randomized trials.60) 
There have only been four published controlled smok-
ing cessation treatment studies in bipolar smokers. The 
first two are relatively small studies, with two recent more 
definitive studies with varenicline. The initial small pilot 
study (n=5) but showed buproprion was well-tolerated 
and potentially useful during 10 weeks of treatment.75) 
Following on from this, Wu et al.76) conducted another ti-
ny (n=5) study of varenicline for tobacco cessation in 
those with bipolar disorder. Over the 10-week treatment 
phase, reduction in tobacco smoking in the varenicline 
group was found and it was well tolerated. In the first large 
randomized controlled trial of varenicline for tobacco ces-
sation maintenance in individuals diagnosed with bipolar 
disorder and schizophrenia, 87 participants were included 
in the maintenance phase, of which only 13 were diag-
nosed with bipolar disorder (the remaining were diag-
nosed with schizophrenia). The study included an 
open-label phase for 12 weeks following which partic-
ipants who were abstinent for at least 14 days were then 
randomized to receive either continued varenicline treat-
ment, or placebo up to 52 weeks of treatment.60) Vareni-
cline was efficacious as a maintenance treatment in the 
study, and this effect remained when those with bipolar 
disorder were analysed separately. The largest and most 
rigorous study was that by Evins et al.,60) who enrolled 
247 smokers with schizophrenia or bipolar disorder from 
10 community mental-health centres. Of these, 203 re-
ceived 12-week treatment with both open-label vareni-
cline and cognitive behavioral therapy, after which 87 met 
abstinence criteria and entered the relapse prevention in-
tervention. After a year, the point-prevalence abstinence 
rates were 60% with varenicline treatment and 19% with 
placebo, giving an odds ratio of 6.2. Importantly, there 
were no impacts on psychiatric symptoms. 
This paper has highlighted that tobacco smoking is del-
eterious to mental health, but a critical question is whether 
mental health benefits from tobacco smoking cessation. A 
critical review and meta-analysis has recently been pub-
lished, with striking findings. Firstly, quitting has been 
linked to reduced anxiety and stress, depression, and im-
proved positive mood as well as quality of life compared 
with ongoing tobacco smoking. Secondly, effect sizes are 
equivalent for people with psychiatric disorders compared 
to those without. Lastly, effect sizes appear similar or 
greater than those of antidepressant treatment for the 
abovementioned disorders.77) This finding highlights the 
necessity to work towards cessation.
It is not clear how best to assist smokers with mental ill-
ness to quit tobacco smoking. There are additional factors 
that may further contribute to the success or failure of 
smoking cessation in those particularly, diagnosed with 
bipolar disorder. Given the high rates of comorbid anxiety 
disorders and substance abuse the complexities of treat-
ment for smoking cessation are increased. George et al.33) 
have suggested that the alternating mood fluctuations 
(ranging from irritable and elevated mood to severe de-
pression) may contribute to differences in smoking cessa-
tion rates found in bipolar disorder. Similarly, Ostacher et 
al.10) reported a relationship between comorbid anxiety 
disorders and substance abuse in lifetime smokers with bi-
polar disorder, suggesting further difficulty in smoking 
cessation. Current smoking cessation interventions for in-
dividuals with bipolar disorder include several first line 
pharmacotherapies that include nicotine replacement 
therapy, bupropion, sustained release and varenicline.3) It 
has also been reported that olanzapine can assist in cue 
prompted cravings for tobacco.70) The problem with most 
of these therapies is that it is unclear how safe and efficient 
these aids are for people with bipolar disorder.3) Unlike 
pharmacotherapy, behavioural interventions have been 
tested but unfortunately, current evidence is insufficient to 
recommend these approaches as alternatives to standard 
counselling.3) However, behavioural interventions im-
prove the chances of quitting, especially when used in 
conjunction with pharmacotherapy.78) Examples of be-
havioural interventions include cognitive behaviour ther-
apy, mood management interventions and motivational 
interviewing. 
Most large studies use mixed populations that are gen-
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erally heavily weighted towards high prevalence disor-
ders. El-Guebaly et al.79) reviewed 24 studies of tobacco 
smoking cessation in people with mental disorder, where 
the majority of interventions combined pharmacothera-
pies and psychoeducation, and found that quit rates for 
people with mental illnesses were similar to those ex-
pected for the general population. On the basis of these 
findings, Australian tobacco smoking cessation programs 
give recommendations for smoking cessation strategies 
for people with mental illnesses that are largely identical 
to recommendations given or people without mental ill-
nesses; apart from warning about altered pharmacoki-
netics of some psychotropic medications, the possibility 
of withdrawal symptoms being mistaken for symptoms of 
mental illness and a risk of exacerbation of depressive 
symptoms. A government funded tobacco smoking cessa-
tion program in Brazil identifies people with mental ill-
nesses and substance abuse and tailored their smoking 
cessation intervention to their needs.80) Kerr and col-
leagues81) describe barriers to mainstream tobacco smok-
ing cessation programs for people with mental illnesses 
that include; perceived benefits of smoking to their symp-
toms of mental illness, fear of illness worsening, social 
circles where smokers predominate, low self-confidence, 
health professionals who are not encouraging their cessa-
tion efforts and are not trained in tobacco smoking cessa-
tion and reluctance to access mainstream smoking cessa-
tion services. Furthermore, health professionals are not al-
ways aware of the importance of addressing smoking ces-
sation in this vulnerable group.82) While there is in-
sufficient evidence to recommend any specific tobacco 
smoking cessation technique for people with bipolar dis-
order, there is sufficient evidence to conclude that tobacco 
smoking cessation interventions should be tailored to the 
individual needs and preferences of the person being 
treated. For some individuals with bipolar disorder main-
stream tobacco smoking cessation techniques may be 
adequate. For other individuals it may be more effective to 
provide tobacco smoking cessation support delivered 
through their usual mental health care provider and pro-
viding support techniques additional to those provided by 
mainstream services. Health professionals should encour-
age smokers with mental illness to cease tobacco smoking.
FUTURE DIRECTIONS FOR RESEARCH: 
TOBACCO SMOKING IN BIPOLAR DISORDER
In this review, an attempt has been made to understand 
the relationship between smoking and bipolar disorder. As 
Pasco et al.83) note, it is becoming increasingly clear that 
tobacco smoking is not only harmful to our physical 
health, but also for our mental health, which may in fact 
contribute to its onset or aggravate current symptoms. 
It is possible that certain individuals are more vulner-
able to nicotine’s psychostimulant properties than others 
and researchers have implied that there is the possibility 
that separate causal mechanisms may operate in a bi-di-
rectional manner.84) Many of the studies evaluated did not 
assess for nicotine dependence, which may play a bigger 
role on nicotine’s effect on mood symptomatology that 
rates of daily smoking. It is also clear that more studies 
need to be conducted to accurately assess the consequ-
ences that dependent tobacco smoking places on bipolar 
disorder. It is suggested that consistent measures of mood 
symptoms as they apply to bipolar disorder are assessed, 
as well as consistent measures to assess nicotine depend-
ence amongst individuals with bipolar disorder. 
In conclusion, people with bipolar disorder have much 
higher tobacco smoking rates compared to the general 
population. Furthermore, although the relationship be-
tween tobacco smoking and bipolar disorder may be bidir-
ectional and that cause and effect may be difficult to de-
termine, the majority of studies reviewed suggest that to-
bacco smoking appears to play a mediating role in the se-
verity of bipolar disorder. Clear gaps exist in the literature, 
and there is a need for researchers to look at formal smok-
ing cessation programs and the relationship between to-
bacco smoking, insomnia, lifestyle factors and quality of 
life in bipolar disorder. Caggiula et al.85) suggest, the 
abuse liability associated with tobacco smoking equals or 
exceeds that of other addictive drugs. It is also suggested 
that tobacco smoking is screened by mental health pro-
fessionals and targeted during routine treatment, with the 
implementation of more formal cessation programs.86)
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